# Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma

**Authors:** Felix Czernilofsky, Anna Mathioudaki, Lea Jopp-Saile, Raphael Lutz, Dominik Vonficht, Xi Wang, Christina Schniederjohann, Harald Voehringer, Tobias Roider, Marc-Andrea Baertsch, Claus Rodemer, Henry Löffler-Wirth, Michael Grau, Donnacha Fitzgerald, Johannes Mammen, Jan Kosla, Nora Liebers, Peter-Martin Bruch, Diana Ordoñez-Rueda, Alexander Brobeil, Gunhild Mechtersheimer, Caroline Pabst, Carsten Müller-Tidow, Andreas Trumpp, Marc Seifert, Frank Neumann, Mathias Heikenwälder, Vladimir Benes, Wolfgang Huber, Jörg Distler, Georg Lenz, Hans Binder, Reiner Siebert, Garry P. Nolan, Moritz Gerstung, Judith B. Zaugg, Daniel Hübschmann, Simon Haas, Sascha Dietrich

PMC · DOI: 10.1038/s43018-026-01136-z · Nature Cancer · 2026-03-25

## TL;DR

The study shows how stromal cell changes in lymph nodes lead to loss of tissue structure in B cell lymphoma, impacting patient survival.

## Contribution

The paper reveals a tumor-reactive T cell-driven inflammatory feedback loop that reprograms stromal cells and disrupts lymph node architecture.

## Key findings

- Stromal cells are central to chemokine-driven lymphocyte organization in healthy lymph nodes.
- Tumor-reactive T cells trigger stromal remodeling and loss of chemokine gradients in follicular and diffuse large B cell lymphoma.
- Loss of homeostatic chemokines correlates with poor patient survival in lymphoma.

## Abstract

Lymph node (LN) function requires the organization of cells into higher-order spatial units. However, the principles governing LN architecture in health and disease remain poorly understood. Here, we used single-cell and spatial mapping to investigate the mechanisms directing immune cell organization in human LNs and its disruption in architecturally distinct lymphoma entities: indolent follicular lymphoma (FL) and aggressive diffuse large B cell lymphoma (DLBCL). Our data substantiate the central role of LN-resident stromal cells in chemokine-driven lymphocyte zonation and reveal an inflammatory feedback loop fueled by tumor-reactive T cells that triggers stromal remodeling, progressive loss of homeostatic chemokine gradients, and tissue disorganization from a non-malignant state to FL and DLBCL. Loss of homeostatic chemokines was associated with adverse patient survival, identifying the underlying architectural rearrangement as a key event during lymphomagenesis. Collectively, our results highlight the principles of LN organization and suggest how lymphoma-induced microenvironmental reprogramming drives the loss of tissue organization.

Czernilofsky et al. identified factors that reprogram stromal cells into an inflammatory, dysfunctional state, leading to the structural disorganization of lymph nodes in B cell lymphoma at single-cell and spatial resolutions.

## Linked entities

- **Diseases:** follicular lymphoma (MONDO:0018906), diffuse large B cell lymphoma (MONDO:0018905)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CXCL13 (C-X-C motif chemokine ligand 13) [NCBI Gene 10563] {aka ANGIE, ANGIE2, BCA-1, BCA1, BLC, BLR1L}, IRF7 (interferon regulatory factor 7) [NCBI Gene 3665] {aka IMD39, IRF-7, IRF-7H, IRF7A, IRF7B, IRF7C}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, TPR (translocated promoter region, nuclear basket protein) [NCBI Gene 7175] {aka MRT79}, STAT2 (signal transducer and activator of transcription 2) [NCBI Gene 6773] {aka IMD44, ISGF-3, P113, PTORCH3, STAT113}, Cxcl13 (C-X-C motif chemokine ligand 13) [NCBI Gene 55985] {aka 4631412M08Rik, ANGIE2, Angie, BCA-1, BLC, BLR1L}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, CD34 (CD34 molecule) [NCBI Gene 947], PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CR2 (complement C3d receptor 2) [NCBI Gene 1380] {aka C3DR, CD21, CR, CVID7, SLEB9}, FLT3LG (fms related receptor tyrosine kinase 3 ligand) [NCBI Gene 2323] {aka FL, FLG3L, FLT3L, IMD125}, Cxcl9 (C-X-C motif chemokine ligand 9) [NCBI Gene 17329] {aka CMK, Mig, MuMIG, Scyb9, crg-10}, Ccl19 (C-C motif chemokine ligand 19) [NCBI Gene 24047] {aka CKb11, ELC, Gm2023, MIP3B, Scya19, exodus-3}, CCL21 (C-C motif chemokine ligand 21) [NCBI Gene 6366] {aka 6Ckine, CKb9, ECL, SCYA21, SLC, TCA4}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, CCL19 (C-C motif chemokine ligand 19) [NCBI Gene 6363] {aka CKb11, ELC, MIP-3b, MIP3B, SCYA19}, Cxcl11 (chemokine (C-X-C motif) ligand 11) [NCBI Gene 56066] {aka Cxc11, H174, I-tac, Ip9, Itac, Scyb11}, Tnfsf13b (tumor necrosis factor (ligand) superfamily, member 13b) [NCBI Gene 24099] {aka BAFF, BLyS, D8Ertd387e, TALL-1, TALL1, THANK}, PDPN (podoplanin) [NCBI Gene 10630] {aka AGGRUS, D2-40, GP36, GP40, Gp38, HT1A-1}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, IRF2 (interferon regulatory factor 2) [NCBI Gene 3660] {aka IRF-2}, EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, CXCR5 (C-X-C motif chemokine receptor 5) [NCBI Gene 643] {aka BLR1, CD185, MDR15}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283] {aka CMK, Humig, MIG, SCYB9, crg-10}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, THY1 (Thy-1 cell surface antigen) [NCBI Gene 7070] {aka CD90, CDw90}, TNFSF13B (TNF superfamily member 13b) [NCBI Gene 10673] {aka BAFF, BLYS, CD257, TALL-1, TALL1, THANK}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, CXCL11 (C-X-C motif chemokine ligand 11) [NCBI Gene 6373] {aka H174, I-TAC, IP-9, IP9, SCYB11, SCYB9B}
- **Diseases:** Lymphoma (MESH:D008223), acute infections (MESH:D000208), EM-II (MESH:C537730), DLBCL (MESH:D016403), inflammation (MESH:D007249), B cell lymphoma (MESH:D016393), LN (MESH:D000072717), FL (MESH:D008224), Cancer (MESH:D009369), FRC dysfunction (MESH:D006331)
- **Chemicals:** oligonucleotides (MESH:D009841), nitrogen (MESH:D009584), EDTA (MESH:D004492), paraffin (MESH:D010232), RPMI 1640 (-), calcein (MESH:C007740), calcium (MESH:D002118), streptomycin (MESH:D013307), formalin (MESH:D005557), COO (MESH:C041069), PBS (MESH:D007854), l-glutamine (MESH:D005973), penicillin (MESH:D010406), DMSO (MESH:D004121)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** LEC — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_VU63), BEC — Mus musculus (Mouse), Hybridoma (CVCL_RQ14)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13035477/full.md

## Figures

15 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13035477/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC13035477/full.md

---
Source: https://tomesphere.com/paper/PMC13035477